(Reuters) -Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a “poison pill”, in response to rapid accumulations of the company’s stock by some investors.
The company also said it had launched a process to evaluate strategic alternatives, including a possible sale of the company.
(Reporting by Manas Mishra in Bengaluru; Editing by Shilpi Majumdar)
